A recovered COVID-19 patient who has become a strong nationwide advocate for the Convalescent Plasma Expanded Access Program made a plasma donation at Mayo Clinic in Rochester. Chaim Lebovits became involved with the program in March and since then has rallied thousands, who have also recovered, to donate.The initiative, which Mayo Clinic is leading, studies the use of plasma from recovered COVID-19 patients to treat patients currently suffering from the illness.
The FDA granted Emergency Use Authorization to Eko, a digital health company, for the heart screening algorithm developed by Mayo Clinic. The AI-driven algorithm can detect weak heart pump, which is commonly detected by echocardiogram, a test that is not normally conducted during a physical exam, requires specially trained technicians to record, and requires prolonged contact with the patient.
Due to the COVID-19 pandemic, hospitals and clinics were forced to postpone nonessential appointments and surgeries in March and April. Thanks to social distancing and executive stay-at-home orders which helped flatten the curve of the COVID-19 outbreak, Mayo Clinic is prepared now, not only to meet the projected needs of COVID-19 patients, but safely treat patients whose care was delayed, and to welcome new patients as well.
Thermo Fisher Scientific Inc. announced it will expand its response to the COVID-19 pandemic by developing a total antibodies test in collaboration with WuXi Diagnostics and Mayo Clinic. The new test is the result of ongoing collaboration between all three organizations, including clinical evaluation and support from Mayo Clinic. Thermo Fisher will seek U.S. FDA Emergency Use Authorization (EUA) and international regulatory authorizations for the test over the next few weeks.